Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aventis
99.9% of S. pneumoniae isolates susceptible to Ketek, per surveillance study
June 26th, 2004
Results from an ongoing surveillance study, PROTEKT U.S. (Prospective Resistant Organism Tracking and Epidemiology of the Ketolide Telithromycin - United States) Year 2 (2001-2002), suggest that Ketek (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates, including those resistant to other antimicrobial agents. These data were presented today at the 100th International Conference of the American Thoracic Society (ATS). Increasing multi-drug resistance among S. pneumoniae isolates compromises the treatment of community-acquired respiratory tract infections. This study found that...
Source: Law & Health Weekly (2004-06-26)
|
